Dementia

Page Contents >

Key findings from PSSRU's research in this area have included:

  • Dementia costs more than £26 billion each year in the UK
  • Two-thirds of the estimated cost of dementia in the UK is shouldered by carers and people with dementia
  • There are approximately 816,000 people today living with dementia in the UK
  • There are an estimated 36.5 million people with dementia, a number that is expected to rise to 115 million people by 2050
  • In England and Wales, there are an estimated 16,683 people aged 75 living with dementia; 56.2% do not have a diagnosis
  • The START intervention is a low-cost intervention that helps carers to develop their coping abilities

Examples of current studies

MODEM: Comprehensive approach to modelling outcome and cost impacts of interventions for dementia
Start date:
1 March 2014
End date: 28 February 2018
Project lead: Professor Martin Knapp, PSSRU LSE
Funder: Economic and Social Research Council & National Institute for Health Research

MODEM - Comprehensive approach to modelling outcome and cost impacts of interventions for dementia - is developing a comprehensive set of quantitative models to forecast how many people will develop dementia in England over the next 30 years; the unpaid support services available from family and other carers; and the projected costs of their treatment and care. The study is a collaboration between researchers from the London School of Economics and Political Science, Newcastle University, the University of Southampton, University of Sussex and the International Longevity Centre-UK. View the project website for more information.

IDEAL: Improving the experience of dementia and enhancing active life: living well with dementia
Start date:
1 January 2014
End date: 31 December 2018
Project lead:
Funder: 
Economic and Social Research Council & National Institute for Health Research

The IDEAL research project focuses on people who have difficulties with memory, thinking or behaviour, that may have been described as dementia or an associated condition, and on the family members or friends who provide support. The aim of the study is to find out what makes it easier or more difficult for people to live well with dementia, and what can be done to help more people to live well with dementia. View the project website for more information.

AFFECT: A randomized controlled trial of calcium channel blockade (CCB) with amlodipine for the treatment of subcortical ischaemic vascular dementia (SIVD) Start date: 13 January 2014 
End date:
12 January 2018
Project lead: Dr Peter Passmore, Queen's University Belfast
Funder: Alzheimer's Society and the British Heart Foundation

Vascular dementia is the second most common form of dementia, affecting an estimated 20% of people with dementia. The most common form of vascular dementia is subcortical ischemic vascular dementia (SIVD), affecting up to 67% of people with vascular dementia. This study aims to investigate whether treatment with the calcium channel blocker medication amlodipine can improve outcomes for people with SIVD. The study will compare amlodipine treatment with a control to see if there is any difference compared to the care people usually receive. PSSRU colleagues are leading the economic evaluation within this study.

Highlighted publications

Dixon J, Ferdinand M, D'Amico F, Knapp M (2015) Exploring the cost-effectiveness of a one-off screen for dementia (for people aged 75 years in England and Wales), International Journal of Geriatric Psychiatry, 30, 5, 446-452.

Knapp M, Comas-Herrera A, Wittenberg R, Hu B, King D, Rehill A, Adelaja B (2014) Scenarios of Dementia Care: What are the Impacts on Cost and Quality of Life? (PDF), Report to the Department of Health, Personal Social Services Research Unit, London **Referenced in the Prime Minister's Challenge on Dementia 2020, 21 February 2015**

Prince M, Knapp M, Guerchet M, McCrone P, Prina M, Comas-Herrera A, Wittenberg R, Adelaja B, Hu B, King D, Rehill A, Salimkumar D (2014) Dementia UK: Update  (PDF), Alzheimer’s Society, London.

Share:Facebook|Twitter|LinkedIn|